Fresh trial launched for ‘COVID-19 drug’ in Japan

In Japan's Phase III testing of its Avigan COVID-19 medicine began on Wednesday, Fujifilm Holdings said it was reviving hopes of a home-grown virus therapy.

The domestic approval for the antiviral medication was reversed in December following the fact that the trial results were inconclusive, according to the medical ministry commission.

Over the years, Fujifilm has turned into a medical company from the conventional camera and office solutions companies.

Over the years, Fujifilm has turned into a medical company from the traditional camera and office solutions companies.

Fujifilm said in a statement that the recent double-blind, placebo-controlled trial focuses on patients aged 50 and over and those at risk of developing severe conditions.

Avigan was tested in dozens of trials worldwide and approved for therapy with COVID-19 in Russia, India, and Indonesia. It is known as favipiravir. There are still questions, as in animal experiments the drug has shown to cause birth defects.

Avigan has now been accepted as an emergency flu medicine by Japan; last year the Fujifilm government asked Fujifilm to stock three times the national medicine.
Close[x]